All Stories

  1. Understanding immunity to influenza: implications for future vaccine development
  2. Interferons—Implications in the Immune Response to Respiratory Viruses
  3. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
  4. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
  5. Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
  6. RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
  7. Influenza B Virus (IBV) Immune-Mediated Disease in C57BL/6 Mice
  8. Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs
  9. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
  10. Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
  11. Structural basis for ultrapotent neutralization of human metapneumovirus
  12. ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
  13. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
  14. Immunopathology of RSV: An Updated Review
  15. MicroRNAs affect GPCR and Ion channel genes needed for influenza replication
  16. Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro
  17. Advances in Vaccine Development
  18. Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs
  19. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein
  20. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
  21. Losartan Inhibits SARS-CoV-2 Replication in Vitro
  22. Innate Antiviral Cytokine Response to Swine Influenza Virus by Swine Respiratory Epithelial Cells
  23. Probenecid Inhibits SARS-CoV-2 Replication In Vivo and In Vitro
  24. G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication
  25. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins
  26. Losartan promotes cell survival following SARS-CoV-2 infection in vitro
  27. Innate and adaptive immune responses in respiratory virus infection: implications for the clinic
  28. Exosome-mediated human norovirus infection
  29. Pathobiology of Respiratory Syncytial Virus (RSV)
  30. Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1
  31. Up-to-date role of biologics in the management of respiratory syncytial virus
  32. Vero Cells as a Mammalian Cell Substrate for Human Norovirus
  33. Emerging small and large molecule therapeutics for respiratory syncytial virus
  34. Gene-edited vero cells as rotavirus vaccine substrates
  35. Original Antigenic Sin and Respiratory Syncytial Virus Vaccines
  36. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo
  37. Human Norovirus: Experimental Models of Infection
  38. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro
  39. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
  40. Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
  41. Viral Modulation of Host Translation and Implications for Vaccine Development
  42. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
  43. A universal mammalian vaccine cell line substrate
  44. Revisiting the RSV G protein as a target for drugs and vaccines.
  45. MicroRNA-134 regulates poliovirus replication by IRES targeting
  46. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge
  47. Respiratory syncytial virus: prospects for new and emerging therapeutics
  48. Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome
  49. Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment
  50. Development of improved vaccine cell lines against rotavirus
  51. Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection
  52. Inhaled Countermeasures for Respiratory Tract Viruses
  53. Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus
  54. Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus)
  55. Development of a Zika vaccine
  56. MicroRNA-555 has potent antiviral properties against poliovirus
  57. Human Respiratory Syncytial Virus
  58. MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples
  59. Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay
  60. Human Respiratory Syncytial Virus: An Introduction
  61. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis
  62. Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease
  63. An innate defence role for BPIFA1/SPLUNC1 against influenza-A virus infection
  64. Antiviral agents for influenza virus
  65. Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression
  66. Polymerase Discordance in Novel Swine Influenza H3N2v Constellations Is Tolerated in Swine but Not Human Respiratory Epithelial Cells
  67. Can an influenza A-based delivery system overcome current challenges associated with miRNA technology?
  68. Frontiers in RNAi
  69. Preface
  70. List of Contributors
  71. Acknowledgments
  72. Author Index
  73. RNAi Screening to Facilitate Drug Repurposing
  74. Subject Index
  75. The Use of RNAi Technology in the Development of High Performance Bioproduction Cell Lines
  76. Virus-Vectored Influenza Virus Vaccines
  77. Identification of Virulence Determinants in Influenza Viruses
  78. Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo
  79. Rapid Identification of Bacterial Pathogens of Military Interest Using Surface-Enhanced Raman Spectroscopy
  80. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)
  81. Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge
  82. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets
  83. Addressing the Re-emergence of Poliovirus
  84. Antiviral Effects of Inhibiting Host Gene Expression
  85. Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
  86. Targeting Fungal Genes by Diced siRNAs: A Rapid Tool to Decipher Gene Function in Aspergillus nidulans
  87. Targeting Cell Division Cycle 25 Homolog B To Regulate Influenza Virus Replication
  88. Modeling Respiratory Syncytial Virus Cytopathogenesis in the Human Airway
  89. Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease
  90. Respiratory Syncytial Virus Infection Induces Higher Toll-Like Receptor-3 Expression and TNF-α Production Than Human Metapneumovirus Infection
  91. Viral Etiology and Clinical Profiles of Children with Severe Acute Respiratory Infections in China
  92. Protective Efficacy and Immunogenicity of a Combinatory DNA Vaccine against Influenza A Virus and the Respiratory Syncytial Virus
  93. Methotrexate Treatment Causes Early Onset of Disease in a Mouse Model of Ross River Virus-Induced Inflammatory Disease through Increased Monocyte Production
  94. A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
  95. Gain-of-Function Experiments on H7N9
  96. Gain-of-Function Experiments on H7N9
  97. Advances in and the potential of vaccines for respiratory syncytial virus
  98. A Novel Influenza Virus Hemagglutinin-Respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine against Influenza and RSV
  99. Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 4 Induces Apoptosis Dependent on Its 3C-Like Serine Protease Activity
  100. Antiviral Responses by Swine Primary Bronchoepithelial Cells Are Limited Compared to Human Bronchoepithelial Cells Following Influenza Virus Infection
  101. Broadening the Heterologous Cross-Neutralizing Antibody Inducing Ability of Porcine Reproductive and Respiratory Syndrome Virus by Breeding the GP4 or M genes
  102. Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs
  103. Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A Virus Infection
  104. A Mechanistic Study on the Destabilization of Whole Inactivated Influenza Virus Vaccine in Gastric Environment
  105. The Role of Interleukin-1 and Interleukin-18 in Pro-Inflammatory and Anti-Viral Responses to Rhinovirus in Primary Bronchial Epithelial Cells
  106. Bat cells from Pteropus alecto are susceptible to influenza A virus infection and reassortment
  107. Vertical Transmission of Respiratory Syncytial Virus Modulates Pre- and Postnatal Innervation and Reactivity of Rat Airways
  108. Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice
  109. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection
  110. Avian Influenza Virus Surveillance in Wild Birds in Georgia: 2009–2011
  111. Adenovirus 36, adiposity, and bone strength in late‐adolescent females
  112. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning
  113. Transmission Studies Resume For Avian Flu
  114. Detection and differentiation of foodborne pathogenic bacteria in mung bean sprouts using field deployable label-free SERS devices
  115. Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis
  116. Risk Assessment and Anti-Viral Approaches for Novel H7N9 Influenza Virus
  117. Therapeutic Considerations for Middle East Respiratory Syndrome Coronavirus
  118. Host Gene Expression and Respiratory Syncytial Virus Infection
  119. Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
  120. Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics
  121. Enzymatically Produced Pools of Canonical and Dicer-Substrate siRNA Molecules Display Comparable Gene Silencing and Antiviral Activities against Herpes Simplex Virus
  122. Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy
  123. Highly Sensitive and Transparent Surface Enhanced Raman Scattering Substrates Made by Active Coldly Condensed Ag Nanorod Arrays
  124. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication
  125. Label-Free Detection of Micro-RNA Hybridization Using Surface-Enhanced Raman Spectroscopy and Least-Squares Analysis
  126. Signal 3 Cytokines as Modulators of Primary Immune Responses during Infections: The Interplay of Type I IFN and IL-12 in CD8 T Cell Responses
  127. A New Model for Hendra Virus Encephalitis in the Mouse
  128. Nucleoprotein Nanostructures Combined with Adjuvants Adapted to the Neonatal Immune Context: A Candidate Mucosal RSV Vaccine
  129. MicroRNA Regulation of Human Protease Genes Essential for Influenza Virus Replication
  130. Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains
  131. The use of a handheld Raman system for virus detection
  132. Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose
  133. Differential Expression of Cytokines in Response to Respiratory Syncytial Virus Infection of Calves with High or Low Circulating 25-Hydroxyvitamin D3
  134. Respiratory Syncytial Virus NS1 Protein Colocalizes with Mitochondrial Antiviral Signaling Protein MAVS following Infection
  135. The C Proteins of Human Parainfluenza Virus Type 1 Block IFN Signaling by Binding and Retaining Stat1 in Perinuclear Aggregates at the Late Endosome
  136. Pause on Avian Flu Transmission Research
  137. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens
  138. Flexible and mechanical strain resistant large area SERS active substrates
  139. Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics
  140. Current Progress on Surface-Enhanced Raman Scattering Chemical/Biological Sensing
  141. Surveillance of feral cats for influenza A virus in North Central Florida
  142. Detection and Differentiation of Avian Mycoplasmas by Surface-Enhanced Raman Spectroscopy Based on a Silver Nanorod Array
  143. Porcine FcγRIIb Mediates Enhancement of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Infection
  144. Humoral and Cell-Mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-Pandemic: Implications for Vaccination
  145. Human Metapneumovirus: Lessons Learned over the First Decade
  146. Increased MDSC Accumulation and Th2 Biased Response to Influenza A Virus Infection in the Absence of TLR7 in Mice
  147. Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells
  148. Exposed Hydrophobic Residues in Human Immunodeficiency Virus Type 1 Vpr Helix-1 Are Important for Cell Cycle Arrest and Cell Death
  149. Evaluation of Protective Efficacy of Respiratory Syncytial Virus Vaccine against A and B Subgroup Human Isolates in Korea
  150. Influenza-Specific T Cells from Older People Are Enriched in the Late Effector Subset and Their Presence Inversely Correlates with Vaccine Response
  151. The Microbial Detection Array Combined with Random Phi29-Amplification Used as a Diagnostic Tool for Virus Detection in Clinical Samples
  152. Circulating Strains of Human Respiratory Syncytial Virus in Central and South America
  153. Interferon Production and Signaling Pathways Are Antagonized during Henipavirus Infection of Fruit Bat Cell Lines
  154. Immunostimulatory Motifs Enhance Antiviral siRNAs Targeting Highly Pathogenic Avian Influenza H5N1
  155. Avian Influenza Viruses Infect Primary Human Bronchial Epithelial Cells Unconstrained by Sialic Acid α2,3 Residues
  156. Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses
  157. Influenza A Virus Nucleoprotein Exploits Hsp40 to Inhibit PKR Activation
  158. Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors
  159. Polarity Changes in the Transmembrane Domain Core of HIV-1 Vpu Inhibits Its Anti-Tetherin Activity
  160. Comparative Pathology in Ferrets Infected with H1N1 Influenza A Viruses Isolated from Different Hosts
  161. Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1)
  162. Universal Oligonucleotide Microarray for Sub-Typing of Influenza A Virus
  163. Comparative Pathogenesis of Three Human and Zoonotic SARS-CoV Strains in Cynomolgus Macaques
  164. Viral and Atypical Bacterial Detection in Acute Respiratory Infection in Children Under Five Years
  165. Aerosol Inoculation with a Sub-lethal Influenza Virus Leads to Exacerbated Morbidity and Pulmonary Disease Pathogenesis
  166. Distinct Roles of Cdc42 in Thymopoiesis and Effector and Memory T Cell Differentiation
  167. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice
  168. A Rapid Flp-In System for Expression of Secreted H5N1 Influenza Hemagglutinin Vaccine Immunogen in Mammalian Cells
  169. Serological Response to the 2009 Pandemic Influenza A (H1N1) Virus for Disease Diagnosis and Estimating the Infection Rate in Thai Population
  170. Detection of Resistance Mutations to Antivirals Oseltamivir and Zanamivir in Avian Influenza A Viruses Isolated from Wild Birds
  171. One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles
  172. Passage of low-pathogenic avian influenza (LPAI) viruses mediates rapid genetic adaptation of a wild-bird isolate in poultry
  173. Application of RNA Interference to Viral Diseases
  174. Effects of Human Respiratory Syncytial Virus, Metapneumovirus, Parainfluenza Virus 3 and Influenza Virus on CD4+ T Cell Activation by Dendritic Cells
  175. Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination
  176. Exploring Cell Tropism as a Possible Contributor to Influenza Infection Severity
  177. Detection of Mycoplasma pneumoniae in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy
  178. A Metagenomic Analysis of Pandemic Influenza A (2009 H1N1) Infection in Patients from North America
  179. Therapeutic targeting of respiratory syncytial virus G-protein
  180. Enhanced Immunogenicity of Stabilized Trimeric Soluble Influenza Hemagglutinin
  181. The Expression of Vasoactive Intestinal Peptide Receptor 1 Is Negatively Modulated by MicroRNA 525-5p
  182. Monomeric and Dimeric CXCL8 Are Both Essential for In Vivo Neutrophil Recruitment
  183. Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins
  184. Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice
  185. The Proapoptotic Influenza A Virus Protein PB1-F2 Forms a Nonselective Ion Channel
  186. Trafficking of Sendai Virus Nucleocapsids Is Mediated by Intracellular Vesicles
  187. A Single Immunization with Soluble Recombinant Trimeric Hemagglutinin Protects Chickens against Highly Pathogenic Avian Influenza Virus H5N1
  188. Phospholipase D1 Mediates TNFα-Induced Inflammation in a Murine Model of TNFα-Induced Peritonitis
  189. Rapid and Sensitive Detection of Rotavirus Molecular Signatures Using Surface Enhanced Raman Spectroscopy
  190. Respiratory Syncytial Virus F and G Proteins Induce Interleukin 1α, CC, and CXC Chemokine Responses by Normal Human Bronchoepithelial Cells
  191. SERS-based viral fingerprinting: current capabilities and challenges
  192. Immunoproteomics Analysis of the Murine Antibody Response to Vaccination with an Improved Francisella tularensis Live Vaccine Strain (LVS)
  193. Pneumovirus and Metapneumovirus: Respiratory Syncytial Virus and Human Metapneumovirus
  194. Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy
  195. Label-free SERS detection of microRNA based on affinity for an unmodified silver nanorod array substrate
  196. Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice
  197. Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
  198. Quantitative Surface-Enhanced Raman Spectroscopy Based Analysis of MicroRNA Mixtures
  199. Emerging Technologies in Nanotechnology-Based Pathogen Detection
  200. Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice
  201. Fabrication and characterization of a multiwell array SERS chip with biological applications
  202. Replication and pathogenesis associated with H5N1, H5N2, and H5N3 low-pathogenic avian influenza virus infection in chickens and ducks
  203. RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
  204. Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway
  205. Optimization of a multi-well array SERS chip
  206. Human Metapneumovirus Establishes Persistent Infection in the Lungs of Mice and Is Reactivated by Glucocorticoid Treatment
  207. The host response and molecular pathogenesis associated with respiratory syncytial virus infection
  208. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice
  209. Therapeutic Applications of RNAi for Silencing Virus Replication
  210. Animal Models for Evaluation of Influenza Vaccines
  211. Spherical and Anisotropic Silver Nanomaterials in Medical Diagnosis
  212. Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS)
  213. Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2
  214. Revised model for early memory T-cell protection against respiratory virus challenge
  215. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15)
  216. RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response
  217. Virally Encoded MicroRNA (miRNA) Candidates for Gene Silencing
  218. Molecular and cellular mechanisms in the viral exacerbation of asthma
  219. Novel nanostructures for SERS biosensing
  220. Infectious Agent Detection With SERS-Active Silver Nanorod Arrays Prepared by Oblique Angle Deposition
  221. An Au/Si hetero-nanorod-based biosensor forSalmonelladetection
  222. Identification and classification of respiratory syncytial virus (RSV) strains by surface-enhanced Raman spectroscopy and multivariate statistical techniques
  223. Serum Mannose-Binding Lectin Levels are Linked with Respiratory Syncytial Virus (RSV) Disease
  224. Evasion of Host Immune Responses by Tumours and Viruses
  225. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge
  226. Bioconjugated nanoparticle detection of respiratory syncytial virus infection
  227. An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection
  228. Rapid and Sensitive Detection of Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate
  229. Silver nanorod arrays as highly sensitive SERS substrates for viral detection
  230. Counting Single Native Biomolecules and Intact Viruses with Color-Coded Nanoparticles
  231. Respiratory Syncytial Virus (RSV) Infects Neuronal Cells and Processes That Innervate the Lung by a Process Involving RSV G Protein
  232. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?
  233. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins
  234. Cytokines and Respiratory Syncytial Virus Infection
  235. Real-Time Detection of Virus Particles and Viral Protein Expression with Two-Color Nanoparticle Probes
  236. The Immune Response to Human Metapneumovirus Is Associated with Aberrant Immunity and Impaired Virus Clearance in BALB/c Mice
  237. Corrigendum to “Serological cross-reactivity of members of the Metapneumovirus genus” [Virus Res. 105 (2004) 67–73]
  238. Human Metapneumovirus Persists in BALB/c Mice despite the Presence of Neutralizing Antibodies
  239. Anti–G Protein Antibody Responses to Respiratory Syncytial Virus Infection or Vaccination Are Associated with Inhibition of G Protein CX3C‐CX3CR1 Binding and Leukocyte Chemotaxis
  240. Serological cross-reactivity of members of the Metapneumovirus genus
  241. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles
  242. Pathogenesis of Respiratory Syncytial Virus Infection
  243. The Brume Surrounding Respiratory Syncytial Virus Persistence
  244. Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness
  245. Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P
  246. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice
  247. The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P
  248. Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection
  249. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection
  250. Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection
  251. Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper–1 and T Helper–2 Cytokines and CC Chemokine Messenger RNA
  252. The Failure of Interleukin-10–deficient Mice to Develop Airway Hyperresponsiveness Is Overcome by Respiratory Syncytial Virus Infection in Allergen–sensitized/challenged Mice
  253. Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus
  254. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
  255. 75th birthday of Professor Ralph Stock
  256. CD4+ T Cell Frequencies and Th1/Th2 Cytokine Patterns Expressed in the Acute and Memory Response to Respiratory Syncytial Virus I-Ed-Restricted Peptides
  257. Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse
  258. TH1- AND TH2-TYPE CYTOKINE EXPRESSION BY ACTIVATED TLYMPHOCYTES FROM THE LUNG AND SPLEEN DURING THE INFLAMMATORY RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS
  259. Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice
  260. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
  261. Influenza Virus (Orthomyxovirus), Infection and Immunity
  262. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections
  263. Tuning into immunological dissonance: an experimental model for infectious mononucleosis
  264. Pathogenesis of an Infectious Mononucleosis-like Disease Induced by a Murine γ-Herpesvirus: Role for a Viral Superantigen?
  265. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
  266. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene
  267. Establishment and Persistence of Virus-Specific CD4+ and CD8+ T Cell Memory
  268. CD8+ T-cell memory to viruses
  269. Cortisol mediated suppression of salmonid lymphocyte responses invitro